(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.85%) $83.14
(-1.16%) $1.619
(-0.48%) $2 335.90
(0.80%) $27.47
(0.52%) $926.90
(-0.16%) $0.933
(-0.16%) $11.01
(-0.25%) $0.798
(0.00%) $92.17
Live Chart Being Loaded With Signals
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men...
Stats | |
---|---|
本日の出来高 | 3 500.00 |
平均出来高 | 60.00 |
時価総額 | 177 659 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0100 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2013-01-25 | Kariv Tomer | Buy | 0 | Common Stock |
2013-01-25 | Kariv Tomer | Buy | 0 | Common Stock |
2013-01-25 | Kariv Tomer | Buy | 0 | Common Stock |
2016-08-15 | Belldegrun Arie | Buy | 714 285 | Common Stock |
2016-08-15 | Belldegrun Arie | Buy | 357 142 | 2016 Series F Warrants (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 89 transactions |
Buy: 17 291 951 | Sell: 681 614 |
Arno Therapeutics, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Arno Therapeutics, Inc. 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $0 |
FY | 2015 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.560 |
FY | 2014 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0.380 |
Financial Reports:
No articles found.
Arno Therapeutics, Inc.
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company's product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。